124 related articles for article (PubMed ID: 38668724)
1. Vascular adhesion protein-1 blockade in primary sclerosing cholangitis: Open-label, multicenter, single-arm, phase II trial.
Hirschfield GM; Arndtz K; Kirkham A; Chen YY; Fox R; Rowe A; Douglas-Pugh J; Thorburn D; Barnes E; Aithal GP; Hull D; Bhandal K; Olsen K; Woodward P; Lax S; Newsome P; Smith DJ; Kallio A; Adams DH; Homer V; Weston CJ
Hepatol Commun; 2024 May; 8(5):. PubMed ID: 38668724
[TBL] [Abstract][Full Text] [Related]
2. Investigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): A single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol.
Arndtz K; Corrigan M; Rowe A; Kirkham A; Barton D; Fox RP; Llewellyn L; Athwal A; Wilkhu M; Chen YY; Weston C; Desai A; Adams DH; Hirschfield GM;
BMJ Open; 2017 Jul; 7(6):e015081. PubMed ID: 28674140
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study.
Eaton JE; Nelson KM; Gossard AA; Carey EJ; Tabibian JH; Lindor KD; LaRusso NF
Scand J Gastroenterol; 2019 May; 54(5):633-639. PubMed ID: 31131678
[No Abstract] [Full Text] [Related]
4. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
Hirschfield GM; Chazouillères O; Drenth JP; Thorburn D; Harrison SA; Landis CS; Mayo MJ; Muir AJ; Trotter JF; Leeming DJ; Karsdal MA; Jaros MJ; Ling L; Kim KH; Rossi SJ; Somaratne RM; DePaoli AM; Beuers U
J Hepatol; 2019 Mar; 70(3):483-493. PubMed ID: 30414864
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study.
Eksteen B; Bowlus CL; Montano-Loza AJ; Lefebvre E; Fischer L; Vig P; Martins EB; Ahmad J; Yimam KK; Pockros PJ; Feld JJ; Minuk G; Levy C
Hepatol Commun; 2021 Mar; 5(3):478-490. PubMed ID: 33681680
[TBL] [Abstract][Full Text] [Related]
6. Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases.
Kurkijärvi R; Adams DH; Leino R; Möttönen T; Jalkanen S; Salmi M
J Immunol; 1998 Aug; 161(3):1549-57. PubMed ID: 9686623
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis.
Hommes DW; Erkelens W; Ponsioen C; Stokkers P; Rauws E; van der Spek M; ten Kate F; van Deventer SJ
J Clin Gastroenterol; 2008; 42(5):522-6. PubMed ID: 18344886
[TBL] [Abstract][Full Text] [Related]
8. Primary sclerosing cholangitis with normal serum alkaline phosphatase activity.
Balasubramaniam K; Wiesner RH; LaRusso NF
Gastroenterology; 1988 Nov; 95(5):1395-8. PubMed ID: 3169503
[TBL] [Abstract][Full Text] [Related]
9. Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis.
Hilscher M; Enders FB; Carey EJ; Lindor KD; Tabibian JH
Ann Hepatol; 2016; 15(2):246-53. PubMed ID: 26845602
[TBL] [Abstract][Full Text] [Related]
10. Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner.
Trivedi PJ; Tickle J; Vesterhus MN; Eddowes PJ; Bruns T; Vainio J; Parker R; Smith D; Liaskou E; Thorbjørnsen LW; Hirschfield GM; Auvinen K; Hubscher SG; Salmi M; Adams DH; Weston CJ
Gut; 2018 Jun; 67(6):1135-1145. PubMed ID: 28428344
[TBL] [Abstract][Full Text] [Related]
11. The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study.
Martin CR; Blanco PG; Keach JC; Petz JL; Zaman MM; Bhaskar KR; Cluette-Brown JE; Gautam S; Sheth S; Afdhal NH; Lindor KD; Freedman SD
Aliment Pharmacol Ther; 2012 Jan; 35(2):255-65. PubMed ID: 22129201
[TBL] [Abstract][Full Text] [Related]
12. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis.
Stanich PP; Björnsson E; Gossard AA; Enders F; Jorgensen R; Lindor KD
Dig Liver Dis; 2011 Apr; 43(4):309-13. PubMed ID: 21251891
[TBL] [Abstract][Full Text] [Related]
13. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
Trauner M; Gulamhusein A; Hameed B; Caldwell S; Shiffman ML; Landis C; Eksteen B; Agarwal K; Muir A; Rushbrook S; Lu X; Xu J; Chuang JC; Billin AN; Li G; Chung C; Subramanian GM; Myers RP; Bowlus CL; Kowdley KV
Hepatology; 2019 Sep; 70(3):788-801. PubMed ID: 30661255
[TBL] [Abstract][Full Text] [Related]
14. Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease.
Muir AJ; Levy C; Janssen HLA; Montano-Loza AJ; Shiffman ML; Caldwell S; Luketic V; Ding D; Jia C; McColgan BJ; McHutchison JG; Mani Subramanian G; Myers RP; Manns M; Chapman R; Afdhal NH; Goodman Z; Eksteen B; Bowlus CL;
Hepatology; 2019 Feb; 69(2):684-698. PubMed ID: 30153359
[TBL] [Abstract][Full Text] [Related]
15. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
[TBL] [Abstract][Full Text] [Related]
16. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial.
Beuers U; Spengler U; Kruis W; Aydemir U; Wiebecke B; Heldwein W; Weinzierl M; Pape GR; Sauerbruch T; Paumgartner G
Hepatology; 1992 Sep; 16(3):707-14. PubMed ID: 1505913
[TBL] [Abstract][Full Text] [Related]
17. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
18. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.
Lynch KD; Chapman RW; Keshav S; Montano-Loza AJ; Mason AL; Kremer AE; Vetter M; de Krijger M; Ponsioen CY; Trivedi P; Hirschfield G; Schramm C; Liu CH; Bowlus CL; Estes DJ; Pratt D; Hedin C; Bergquist A; de Vries AC; van der Woude CJ; Yu L; Assis DN; Boyer J; Ytting H; Hallibasic E; Trauner M; Marschall HU; Daretti LM; Marzioni M; Yimam KK; Perin N; Floreani A; Beretta-Piccoli BT; Rogers JK; ; Levy C
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):179-187.e6. PubMed ID: 31100458
[TBL] [Abstract][Full Text] [Related]
19. Detection of circulating intercellular adhesion molecule-1 in chronic liver diseases.
Adams DH; Mainolfi E; Burra P; Neuberger JM; Ayres R; Elias E; Rothlein R
Hepatology; 1992 Sep; 16(3):810-4. PubMed ID: 1354635
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
